Description
Leading-edge research and technologies that facilitate drug discovery This definitive compilation of information on current drug discovery research reviews?some of the most important topics in post-genomic?biomedical and biopharmaceutical science, such as pharmacogenomics, structure-based drug design, medicinal chemistry, chemical biology, cancer biology, neuroscience, bio-nanotechnology, and stem cell research. Including a Foreword by the late Nobel laureate Paul C. Lauterbur, and with contributions from seventy scholars and researchers from around the world, this book incorporates a general introduction to and practical examples of some of the many methods and techniques for the research of biopharmaceutical discovery in the post-genomic era. The contributors include experts in chemistry, structural biology, computation, biology, and medicine who have a common interest in translating research discoveries into new human therapies. In addition to exploring recent advances, they share their perspectives on various aspects of drug discovery research in the future. Drug Discovery Research: New Frontiers in the Post-Genomic Era is a hands-on resource for practitioners and researchers in the pharmaceutical field and related industries, as well as a valuable reference for students in pharmaceutical science, chemistry, biology, biophysics, bioengineering, pharmacy, and medicine. Ziwei Huang, PHD, is Professor at the Burnham Institute for Medical Research and Adjunct Professor at the University of California at San Diego. He was previously Assistant Professor at Thomas Jefferson University in Philadelphia (1995-2000) and tenured Associate Professor at the University of Illinois at Urbana-Champaign (2000-2004). The author or coauthor of numerous publications and patents, Professor Huang has conducted research in cross-disciplinary areas related to drug discovery, medicinal chemistry, biochemistry, and chemical biology and has developed novel therapeutic agents and research probes for treating or studying human diseases. He has organized many international conferences and workshops in drug discovery research in America and Asia. Additionally, Professor Huang has had close interaction with the biotechnology and pharmaceutical industries as the founder of several biopharmaceutical companies and consultant for many major biotechnology and pharmaceutical companies. FOREWORD. INTRODUCTION. CONTRIBUTORS. PART I. COMPUTATIONAL AND STRUCTURAL APPROACHES IN DRUG DISCOVERY. CHAPTER 1. MOLECULAR DOCKING AND STRUCTURE-BASED DESIGN. CHAPTER 2. RECENT ADVANCES IN DRUG DISCOVERY RESEARCH USING STRUCTURE-BASED VIRTUAL SCREENING TECHNIQUES: EXAMPLES OF SUCCESS FOR DIVERSE PROTEIN TARGETS. CHAPTER 3. VIRTUAL SCREENING IN DRUG DISCOVERY. CHAPTER 4. COMPUTER-AIDED DRUG DESIGN. CHAPTER 5. FOCUSED LIBRARY DESIGN BASED ON HIT AND TARGET STRUCTURES: METHOD AND APPLICATION IN DRUG DISCOVERY. PART II. CHEMICAL AND SYNTHETIC APPROACHES IN DRUG DISCOVERY. CHAPTER 6. BEYOND NATURAL PRODUCTS: SYNTHETIC ANALOGUES OF BRYOSTATIN 1. CHAPTER 7. THE PROMISES AND PITFALLS OF SMALL-MOLECULE INHIBITION OF POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG). CHAPTER 8. CYCLIC ADP-RIBOSE ANALOGUES WITH MINIMAL STRUCTURE: SYNTHESIS AND CALCIUM-RELEASE ACTIVITY. CHAPTER 9. EVALUATION OF NEUROIMMUNOPHILIN LIGANDS. CHAPTER 10. CHIRAL DRUGS AND THE ASSOCIATED ASYMMETRIC SYNTHESIS. CHAPTER 11. ALPHA-HELIX MIMETICS IN DRUG DISCOVERY 281 CHAPTER 12. BASIC AND TRANSLATIONAL RESEARCH OF CHEMOKINE LIGANDS AND RECEPTORS AND DEVELOPMENT OF NOVEL THERAPEUTICS. CHAPTER 13. RESEARCH PROGRESS IN PROTEIN POST-TRANSLATIONAL MODIFICATION. CHAPTER 14. CONTROLLED RELEASE OFANTIBIOTICS ENCAPSULATED IN NANOPOROUS SOL-GEL MATERIALS WITH TUNABLE PORE PARAMETERS. PART III. BIOLOGICAL APPROACHES AND TRANSLATIONAL RESEARCH IN DRUG DISCOVERY. CHAPTER 15. RETINOIC ACID AND ARSENIC TRIOXIDE TREATMENT IN ACUTE PROMYELOCYTIC LEUKEMIA: A MODEL OF ONCOPROTEIN TARGETED THERAPY. CHAPTER 16. 2-CHLORODEOXYADENOSINE. CHAPTER 17. APOPTOSIS-BASED DRUG DISCOVERY FOR CANCER. CHAPTER 18. MECHANISM-BASED DEVELOPMENT OF MEMANTINE AS A THERAPEUTIC AGENT IN TREATING ALZHEIMER’S DISEASE AND OTHER NEUROLOGIC DISORDERS: LOW-AFFINITY, UNCOMPETITIVE ANTAGONISM WITH FAST OFF-RATE. CHAPTER 19. BRIDGING BENCH TO CLINIC: ROLES OFANIMAL MODELS FOR POST-GENOMICS DRUG DISCOVERY ON METABOLIC DISEASES. CHAPTER 20. STEM CELL RESEARCH AND APPLICATIONS FOR HUMAN THERAPIES. INDEX.
